Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity".
about
Challenging hepatitis C-infected liver transplant patientsHepatitis C in non-hepatic solid organ transplant candidates and recipients: A new horizonEra of direct acting antivirals in chronic hepatitis C: Who will benefit?Hepatitis C: New challenges in liver transplantationThe Impact of Infection on Chronic Allograft Dysfunction and Allograft Survival After Solid Organ TransplantationEnhancing our understanding of current therapies for hepatitis C virus (HCV)Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine designSofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report.Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?Structure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526.Response-Guided Therapy for Hepatitis C Virus Recurrence Based on Early Protocol Biopsy after Liver TransplantationPharmaceutical management of hepatitis B and C in liver and kidney transplant recipients.Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis.Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace.Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review.Lycorine-derived phenanthridine downregulators of host Hsc70 as potential hepatitis C virus inhibitors.Genotype 3 and higher low-density lipoprotein levels are predictors of good response to treatment of recurrent hepatitis C following living donor liver transplantation.Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C.Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation.Evaluation of safety of concomitant splenectomy in living donor liver transplantation: a retrospective study.Sofosbuvir and velpatasvir for the treatment of hepatitis C.Should organs from hepatitis C virus-infected donors be used for transplantation in the era of DAAs?Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients.The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.Splenectomy is not indicated in living donor liver transplantation.Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes.Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation.A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.Decreased survival in hepatitis C patients with monomorphic post-transplant lymphoproliferative disorder after liver transplantation treated with frontline immunochemotherapy.
P2860
Q26765020-FC5A08C3-6869-42CF-AB74-EF50E3999D54Q26773201-486C03FA-2BF8-458F-BD11-49CB45E0FC2CQ26777506-59BA7C28-9D87-4E51-8107-4CEAB7D9B052Q26999368-292AE476-2F15-435C-A497-9BD50F006B5DQ28085440-4AE9426B-F0F1-4231-8510-8D38AB7ADF9DQ28085718-8F162763-BC9B-4169-804B-24C35C603EB4Q30374314-63F0BDBB-0B81-4A54-8F0A-8E17E58D4355Q35228316-3B40F500-40AE-43D8-BD66-20DDDDA81327Q35790393-C30ED0BE-2F25-43A8-904E-BB789D958424Q35912053-64080E27-3A0A-4649-8A66-9B2796B073B2Q36241697-E089B94C-DD87-4C95-80AE-68A069237584Q36254143-06BE1ACD-9F2F-49E6-B94F-7020F14E9F56Q37098646-1A25007E-B6B8-42FC-ADF6-967F2AEE4F31Q38515906-A76122A5-5F6D-489A-9430-EB2F4E447027Q38850965-2C5903AF-A336-4870-92A5-0F57E08218B3Q38874771-BB6133FA-993A-4A9D-96D6-4F2FE632C2EDQ38881202-1123C7EE-DD88-4A32-9695-3F8E9F77F373Q38961331-B9045B8D-B3DD-468E-B0B2-862EEE0D0046Q39108672-07D65B87-C70B-4072-8BD7-87F95C36EBC6Q40035445-0238DED2-0F0E-4F10-BD41-AA844B84D8EDQ40141719-149C6ABF-3B38-4742-A369-861ECAB9C9A3Q40203016-B67F2077-DCB9-407B-ABAD-37FFE661CE54Q40209610-50BEC641-B531-4A48-9148-A03DD8B5B3BCQ40216918-CAFFC96B-B401-4213-8847-5E85FC5F0839Q40238114-5AD8D64B-A27C-4600-9BFD-E1CB1F12A4FCQ40272838-A2E02148-007B-41F8-8DF1-A2DA8412C7DAQ40473486-2D6B78A4-0735-431F-91B1-0E6115CFCBDFQ40486090-5494619D-C56B-4521-A4C7-2C85B1067C39Q40576603-6366227A-16D3-4011-AEDD-E7E60DE3BDBDQ40625859-10E05F78-BDCB-48B4-B783-5A7FB6C7E9C4Q41085476-A7EC76FF-C0B3-43AC-A848-D4355E3BDDEDQ41672361-4A5F22E6-164F-4337-894D-49136563C7D6Q42183060-812CFC29-EDA1-4572-AFD0-88CE40E8342EQ47564274-29E079DC-E6F4-45FD-B4F3-D88304BBBFAF
P2860
Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity".
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Directly acting antivirals (DA ...... nts: "a flood of opportunity".
@en
type
label
Directly acting antivirals (DA ...... nts: "a flood of opportunity".
@en
prefLabel
Directly acting antivirals (DA ...... nts: "a flood of opportunity".
@en
P2860
P356
P1476
Directly acting antivirals (DA ...... nts: "a flood of opportunity".
@en
P2093
P2860
P304
P356
10.1111/AJT.12714
P407
P577
2014-04-14T00:00:00Z